Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
Bombardier Positions Challenger 3500 Business Jet Mockup in Olbia, Italy, For Customer Viewings Throughout the Summer